Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Neoplasms 51Multiple Myeloma 42Lymphoma 42Neoplasm Metastasis 41Lung Neoplasms 38Breast Neoplasms 38Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 31Leukemia, Myeloid, Acute 30Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 26Hematologic Neoplasms 24Pancreatic Neoplasms 22Urinary Bladder Neoplasms 21Lymphoma, Non-Hodgkin 21Glioma 21Carcinoma, Renal Cell 19Sarcoma 18Myelodysplastic Syndromes 16Burkitt Lymphoma 16Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Neuroblastoma 14Colonic Neoplasms 14Brain Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 13Fallopian Tube Neoplasms 13

Interventions

Miransertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Proteus Syndrome × 30 days × Clear all
NCT04316546 2026-06-04

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
38 enrolled

Proteus Syndrome

NCT00001403 2026-05-22

Study of Proteus Syndrome and Related Congenital Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
1,500 enrolled

Abnormalities, Multiple, Growth Disorders, Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡